Topics
Glioblastoma | Treatment | Targeted therapy | Erdafitinib
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Erdafitinib
Cabezas-Camarero S, Pérez-Alfayate R, Polidura C,
Gómez-Ruiz MN, Gil-Martínez L, Casado-Fariñas
I, Bartolomé J, Pérez-Segura P.
Durable
benefit and slowdown in
tumor growth dynamics with erdafitinib in a FGFR3-TACC3
fusion-positive IDH-wild type glioblastoma.
Neurooncol
Adv. 2024 Aug 6;6(1):vdae139. doi:
10.1093/noajnl/vdae139. PMID:
39211518. Case report. ˍ